Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 7Completed 5Active not recruiting 5

Sponsor Class

OTHER 6NETWORK 1

Study Type

Interventional 7

Sponsor

Cancer Type

Dermatologic 2Tumor-Agnostic 1Thoracic 1Plasma cell 1Lymphoid 1Gynecologic 1CNS 1

Conditions

Skin Neoplasms 1Platinum-Resistant Fallopian Tube Carcinoma 1Neoplasms 1Multiple Myeloma 1Meningioma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1

Interventions

Specimen Handling 481pembrolizumab 454Magnetic Resonance Spectroscopy 419Carboplatin 321Cyclophosphamide 314Biopsy 272Cisplatin 264Radiotherapy 239Paclitaxel 226Gemcitabine 222Bevacizumab 212Nivolumab 189fludarabine 183venetoclax 172Drug Therapy 165Dexamethasone 157Blood Specimen Collection 156Oxaliplatin 154Injections 152Capecitabine 152Fluorouracil 144Docetaxel 142Standard of Care 136Radiosurgery 136Rituximab 125Pemetrexed 115durvalumab 113atezolizumab 110Leucovorin 110Radiation 105

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Recruiting × HhAntag691 × 1 year × Clear all
NCT02523014 2026-06-02

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Alliance for Clinical Trials in Oncology

Phase 2 Recruiting
124 enrolled
CNS

Meningioma

NCT05651828 2026-04-01

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Recruiting
34 enrolled
Dermatologic

Skin Neoplasms

NCT03297606 2026-03-27

CAPTUR

Canadian Cancer Trials Group

Phase 2 Recruiting
720 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT06616623 2026-02-27

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
24 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05538091 2025-11-26

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

University of Pittsburgh

Phase 2 Recruiting
48 enrolled
Gynecologic

Platinum-Resistant Fallopian Tube Carcinoma

NCT05561634 2025-09-30

RADIOSONIC

University Hospital, Lille

Phase 2 Recruiting
82 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT04341181 2025-07-25

ProTarget

Rigshospitalet, Denmark

Phase 2 Recruiting
300 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡